AT357703B - Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen - Google Patents

Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen

Info

Publication number
AT357703B
AT357703B AT913976A AT913976A AT357703B AT 357703 B AT357703 B AT 357703B AT 913976 A AT913976 A AT 913976A AT 913976 A AT913976 A AT 913976A AT 357703 B AT357703 B AT 357703B
Authority
AT
Austria
Prior art keywords
16alfa
6alfa
17alfa
9alpha
11beta
Prior art date
Application number
AT913976A
Other languages
English (en)
Other versions
ATA913976A (de
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25717430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT357703(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH1615175A external-priority patent/CH621801A5/de
Priority claimed from LU75903A external-priority patent/LU75903A1/xx
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Priority to AT0081179A priority Critical patent/AT363200B/de
Priority to AT0081279A priority patent/AT363201B/de
Priority to AT81079A priority patent/AT363199B/de
Publication of ATA913976A publication Critical patent/ATA913976A/de
Application granted granted Critical
Publication of AT357703B publication Critical patent/AT357703B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT913976A 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen AT357703B (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT0081179A AT363200B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha, 21-dihalogen-11beta, 17alpha-dihydroxy-6alpha-
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-
AT81079A AT363199B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-flour-16alpha-methyl-pregna-1,4-dien-3,20-dion-verbindungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1615175A CH621801A5 (en) 1975-12-12 1975-12-12 Process for the preparation of polyhalosteroids
LU75903A LU75903A1 (de) 1976-09-29 1976-09-29

Publications (2)

Publication Number Publication Date
ATA913976A ATA913976A (de) 1979-12-15
AT357703B true AT357703B (de) 1980-07-25

Family

ID=25717430

Family Applications (2)

Application Number Title Priority Date Filing Date
AT913976A AT357703B (de) 1975-12-12 1976-12-10 Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT0081279A AT363201B (de) 1975-12-12 1979-02-02 Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta,17alpha-dihydroxy-6alpha-

Country Status (16)

Country Link
US (1) US4619921A (de)
JP (1) JPS5289662A (de)
AT (2) AT357703B (de)
AU (1) AU508224B2 (de)
CA (1) CA1056371A (de)
DD (1) DD128683A5 (de)
DE (1) DE2655570A1 (de)
DK (1) DK143708C (de)
ES (1) ES454120A1 (de)
FR (1) FR2334363A1 (de)
GB (1) GB1537130A (de)
HU (1) HU175583B (de)
IE (1) IE44473B1 (de)
IL (1) IL51087A (de)
NL (1) NL7613791A (de)
NZ (1) NZ182836A (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209140B (it) * 1979-11-16 1989-07-10 Prochem Ets 6 alfa-fluoro-prednisolone 17,21-diesteri.
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
IT1319663B1 (it) * 2000-11-17 2003-10-23 Farmabios Srl Processo per la preparazione di fluoro-steroidi.
CN1596241A (zh) 2001-11-29 2005-03-16 塔罗制药美国公司 6α－氟皮质甾类的制备方法
US20040138192A1 (en) * 2003-01-13 2004-07-15 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2006110534A2 (en) 2005-04-07 2006-10-19 Taro Pharmaceuticals U.S.A., Inc. A process for preparing a crystalline form of halobetasol propionate
EP1934219A1 (de) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituierte pyrazolo-[3,4-b]-pyridine als phosphodiesterase-inhibitoren
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
KR20090069309A (ko) * 2006-09-22 2009-06-30 랜박시 래보러터리스 리미티드 포스포디에스터라제 타입-ⅳ의 저해제
EP2066661A2 (de) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
KR102779108B1 (ko) 2015-06-18 2025-03-07 밸리언트 파마슈티컬즈 노오쓰 아메리카 엘엘씨 건선을 치료하기 위한 코르티코스테로이드 및 레티노이드를 포함하는 국소 조성물
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL241055A (de) * 1958-07-09
US3499016A (en) * 1958-08-04 1970-03-03 Upjohn Co 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series
GB898292A (en) * 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH510655A (de) * 1967-11-17 1971-07-31 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
US3718673A (en) * 1971-02-01 1973-02-27 Du Pont Process for the preparation of 21-chloro-6,6,9alpha-trifluoro-11beta, alpha, 17alpha-trihydroxy-1,4-pregnadien-3,20-dione 16,17-ketals and selected intermediates
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US3992422A (en) * 1975-08-14 1976-11-16 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes

Also Published As

Publication number Publication date
ATA913976A (de) 1979-12-15
FR2334363A1 (fr) 1977-07-08
IE44473L (en) 1977-06-12
JPS5289662A (en) 1977-07-27
IE44473B1 (en) 1981-12-16
AU2047276A (en) 1978-06-15
DK143708C (da) 1982-03-15
IL51087A (en) 1980-06-30
GB1537130A (en) 1978-12-29
FR2334363B1 (de) 1980-03-14
CA1056371A (en) 1979-06-12
US4619921A (en) 1986-10-28
DK557876A (da) 1977-06-13
NZ182836A (en) 1979-01-11
DD128683A5 (de) 1977-12-07
NL7613791A (nl) 1977-06-14
ATA81279A (de) 1980-12-15
DK143708B (da) 1981-09-28
HU175583B (hu) 1980-09-28
DE2655570A1 (de) 1977-06-16
ES454120A1 (es) 1978-02-16
IL51087A0 (en) 1977-02-28
AT363201B (de) 1981-07-27
AU508224B2 (en) 1980-03-13

Similar Documents

Publication Publication Date Title
AT357703B (de) Verfahren zur herstellung von neuen 9alpha,21- dihalogen-11beta, 17alfa-dihydroxy-6alfa-fluor- 16alfa-methyl-pregna-1,4-dien-3,20-dion-ver- bindungen
AT365579B (de) Verfahren zur herstellung von neuen tetrahydroisochinoliniumverbindungen
AT360663B (de) Verfahren zur herstellung von neuen 6,7- -benzomorphanen
AT345457B (de) Verfahren zur herstellung von neuen glycosidverbindungen
AT344896B (de) Verfahren zur herstellung von neuen piperazinyliminorifamycinen
AT349633B (de) Verfahren zur herstellung von neuen dauno- saminylanthracylcinonen
AT356671B (de) Verfahren zur herstellung von neuen n,n'-thio- -di-carbamaten
AT353956B (de) Verfahren zur herstellung von neuen cephalosporinantibiotika
ATA585876A (de) Verfahren zur herstellung von neuen 2-benzimidazolylcarbamaten
AT354434B (de) Verfahren zur herstellung von neuen 1,4- diphenyl-3-pyrazolin-5-onen
AT363197B (de) Verfahren zur herstellung von neuen 9alpha,21-dihalogen-11beta, 17alpha-dihydroxy-6alpha-fluor-16beta-methyl-pregna-1,4-dien-3,20-dion-verbindungen
AT344150B (de) Verfahren zur herstellung von neuen cyclohexylphenylen
AT349142B (de) Verfahren zur herstellung von neuen rifamyzin- verbindungen
AT357698B (de) Verfahren zur herstellung von neuen octapeptid- derivaten
AT353989B (de) Verfahren zur herstellung von neuen 11,12- ungesaettigten 9alpha-fluorsteroiden
ATA81179A (de) Verfahren zur herstellung von neuen 9alpha, 21- -dihalogen-11beta, 17alpha-dihydroxy-6alpha- -fluor-16alpha-methyl-pregna-1,4-dien-3-20- -dion-verbindungen
AT356298B (de) Verfahren zur herstellung von neuen 6-amino- methylcholest-5-enen
AT345801B (de) Verfahren zur herstellung von neuen 1-phenoxy- 2-acyloxy-3-amino-propanderivaten
ATA81079A (de) Verfahren zur herstellung von neuen 9alpha,21- -dihalogen-11beta,17alpha-dihydroxy-6alpha- -flour-16alpha-methyl-pregna-1,4-dien-3,20- -dion-verbindungen
AT356125B (de) Verfahren zur herstellung von neuen 1-aryloxy- -2,3-epoxypropanen
AT347967B (de) Verfahren zur herstellung von neuen biguaniden
AT342617B (de) Verfahren zur herstellung von neuen 1-methyl-3-alkyl-7-oxoalkylxanthinen
ATA460476A (de) Verfahren zur herstellung von neuen monodeuterierten prostaglandinen
ATA491279A (de) Verfahren zur herstellung von neuen 2,9-alpha-
ATA160279A (de) Verfahren zur herstellung von neuen unsymetrischen n,n'-thio-di-carbamaten

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee